Theraclion Announces Exclusive Distribution Agreement with EDAP TMS France
EDAP France to Market Echotherapy for ablation of breast fibroadenomas and benign thyroid nodules
THERACLION today announced the signature of an Agreement with EDAP TMS SA, to exclusively distribute Theraclion’s Echopulse® system in France. Originated as a spin-off from EDAP, the global leader in therapeutic ultrasound specialized in urology, Theraclion has developed echotherapy in the use of two indications, fibroadenoma of the breast and benign thyroid nodules and successfully expanded its commercialization efforts in Europe and Asia with key markets being Germany and Hong-Kong. The companies have partnered closely for years and their commercial teams address the same clinics and hospitals.